Skip to main content

Table 2 Student t-test and analysis of variance (ANOVA) between averages for categoric variables

From: Clinical variables influencing the perception of fatigue in people with multiple sclerosis: a cross-sectional study using FSIQ-RMS

 

24hours_FSIQ-RMS

Mean, standard deviation

P value

7days_FSIQ-RMS

Mean, standard deviation

P value

Gender

 Female

29.58 (± 17.190)

0.576

17.16 (± 10.546)

0.454

 Male

30.24 (± 18.462)

16.72 (± 11.224)

Body Mass Index (BMI)

 Underweight

47.73 (± 16.341)

0.003**

27.45 (± 8.501)

0.002**

 Healthy

28.72 (± 17.676)

16.14 (± 10.185)

 Overweight

27.21 (± 16.130)

15.64 (± 10.631)

 Obese

32.82 (± 12.679)

21.64 (± 12.307)

Education

 Elementary school

42,50 (± 10.607)

0.632

15,50 (± 3.536)

0.213

 Middle school

31,79 (± 17.931)

20,39 (± 11.755

 High school

29,07 (± 17.287)

17,01 (± 10.962)

 Three-year degree

24,83 (± 12.583)

11,75 (± 6.662)

 Master’s degree

30,40 (± 18.751)

16,58 (± 10.327)

Disease modyfing therapies (DTMs)

 METs

29,08 (± 17.381)

0.601

15,77 (± 9.840)

0.333

 HETs

34,65 (± 19.289)

19,68 (± 11.438)

 W_DMTs

27,00 (± 17.016)

17,19 (± 11.287)

Physiotherapy training during study

 Yes

32.15 (± 17.229)

0.281

20.30 (± 10.458)

0.016*

 No

28.92 (± 17.550)

15.92 (± 10.580)

Working status during study

 Yes

29.33 (± 18.243)

0.658

15.45 (10.414)

0.006**

 No

30.55 (± 16.058)

20.03 (10.654)

  1. 24h_FSIQ-RMS = 24 h total score Fatigue severity impact scale-relapsing Multiple Sclerosis; 7d_FSIQ-RMS = 7 days total score fatigue severity impact scale-relapsing Multiple Sclerosis; METs = Moderate Efficacy therapies; HETs = High Efficacy therapies; W_DMTs = Without_Disease modyfing therapies
  2. *Statistical significance for p < 0.05
  3. **Statistical significance for p < 0.01